[Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors].
OBJECTIVE
To detect and analysis epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog deleted on chromosome ten (PTEN) in different malignancy brain tumors, and to evaluate their prognostic significance.


METHODS
Using immunohistochemistry to detect the expression of EGFR and PTEN and adopting confocal technology to verify their location in the specimens of 25 respectively glioblastoma multiformes, medulloblastomas, anaplastic oligodendrogliomas, and anaplastic ependymomas.


RESULTS
76% of glioblastoma multiformes had amplification of EGFR, and 40% of which lost PTEN. Patients with these phenomena had a poor survival prognosis, 7 months VS 18 months. However amplification of EGFR and deletion of PTEN were relatively low in other malignancy brain tumors. They were 36% and 8% in medulloblastomas, and 28% and 8% in anaplastic oligodendrogliomas, and 24% and 4% in anaplastic ependymomas.


CONCLUSIONS
PTEN mutation and EGFR amplification are important prognostic factors in patients with glioblastoma multiformes. PTEN mutation and EGFR overexpression are rare in medulloblastoma, anaplastic oligodendroglioma, and anaplastic ependymoma, so the EGFR or PTEN targeted antitumor approaches may be useful in glioblastoma multiformes but the other 3 tumors.
Liu
Jia-Gang
JG
Department of Nearosurgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Liu
Yan-Hui
YH
Cai
Jing
J
Liu
Xue-Song
XS
Song
Wei-Zheng
WZ
Huang
Yi
Y
Mao
Qing
Q
D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis / Q000235:genetics*; D002648:Child; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D011379:Prognosis; D055815:Young Adult
D066246:ErbB Receptors; D051059:PTEN Phosphohydrolase